SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) trades at a trailing P/E of 11.8, forward P/E of 0.5. Trailing earnings yield is 8.47%, forward earnings yield 204.08%. PEG 0.03 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (100/100, Pass) — P/E is below market average (11.8); PEG ≤ 1.0 — Peter Lynch undervalued (0.03); earnings yield beats bond yields (8.47%).
- Forward P/E 0.5 (down from trailing 11.8) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.03 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 8.47% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 204.08% as earnings recover.
Overall SharesGrow Score: 78/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — GNMLF
Valuation Multiples
P/E (TTM)11.8
Forward P/E0.5
PEG Ratio0.03
Forward PEG0.03
P/B Ratio0.00
P/S Ratio1.08
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.09
Forward EPS (Est.)$2.19
Book Value / Share$0.00
Revenue / Share$1.00
FCF / Share$0.00
Yields & Fair Value
Earnings Yield8.47%
Forward Earnings Yield204.08%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-0.08 |
$549.3M |
$-81.59M |
-14.9% |
| 2017 |
$0.07 |
$617.33M |
$65.38M |
10.6% |
| 2018 |
$0.06 |
$598.89M |
$56.34M |
9.4% |
| 2019 |
$0.04 |
$673.21M |
$40.48M |
6% |
| 2020 |
$0.07 |
$696.1M |
$70.44M |
10.1% |
| 2021 |
$0.06 |
$754.1M |
$63.68M |
8.4% |
| 2022 |
$0.07 |
$862.36M |
$71.22M |
8.3% |
| 2023 |
$0.07 |
$969.48M |
$63.89M |
6.6% |
| 2024 |
$1.53 |
$18.61B |
$1.49B |
8% |
| 2025 |
$0.09 |
$973.01M |
$89.16M |
9.2% |
